Where is Kymera Therapeutics' corporate headquarters? Kymera Therapeutics Completes $30 Million Series A ... The Life Sciences team advised Kymera Therapeutics LLC on its $30 million Series A financing round to advance a transformational new therapeutic modality and discover breakthrough medicines for patients with previously untreatable diseases. Company Kymera Therapeutics News, Employees and Funding ... Therefore, from . Kymera Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Glassdoor gives you an inside look at what it's like to work at Kymera Therapeutics, including salaries, reviews, office photos, and more. Kymera Therapeutics Interview Questions | Glassdoor Kymera Therapeutics, Inc. (KYMR) Stock Price, News, Quote ... Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera Therapeutics to Participate in Upcoming January and ... Join Ladders to find the latest jobs at Kymera Therapeutics and get noticed by over 90,000 recruiters. Show more Kymera Therapeutics headquarters is in Watertown, MA. 75% of employees would recommend working at Kymera Therapeutics to a friend and 75% have a positive outlook for the business. Shares of protein degradation biotech Kymera Therapeutics, Inc. (KYMR) are down some 40% from their January 3rd, 2022 close on little news, as the entire space has come under pressure. When Kymera Therapeutics last reported its balance sheet in September 2021, it had zero debt and cash worth US$536m. Laurent joined Kymera Therapeutics from Pierre Fabre, where he was the Global Head of R&D and a managing partner at the PF fund for innovation. Kymera Therapeutics' headquarters are located at 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472. Kymera Therapeutics Corporate Headquarters, Office ... Kymera Therapeutics Employer Profile - MassBio Career Center Location: Cambridge, MA Add to My Lists. Laurent Audoly, President & CEO, Kymera Therapeutics Laurent started his drug development career at Pfizer, where he led multiple discovery efforts in inflammation and immunology . The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Find 27 available jobs at Kymera Therapeutics with Ladders. Kymera Therapeutics's main competitors include Foghorn Therapeutics, Urovant Sciences, Praxis Precision Medicines and Cellenkos. Kymera Therapeutics is headquartered in Watertown, MA and has 2 office locations across 1 country. IPO Launch: Kymera Therapeutics Proposes $125 Million IPO ... Dr. Maraganore joins Kymera's Board after having led Alnylam Pharmaceuticals as founding CEO and . Kymera Therapeutics (NASDAQ:KYMR) Analyst Ratings - Benzinga It focuses on discovering and developing novel small molecule therapeutics. Kymera's proprietary . Name: Kymera Therapeutics Industry: Biotechnology Location: Watertown, MA, United States Employees: 100-200 Description: Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the bo. A free inside look at Kymera Therapeutics salary trends based on 4 salaries wages for 4 jobs at Kymera Therapeutics. Kymera Therapeutics, Inc. (KYMR) SEC Filing 10-K Annual Report for the fiscal year ending Friday, December 31, 2021. Kymera is accelerating drug discovery with an unmatched ability to target and . About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Kymera Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT05225584 Other Study ID Numbers: KT333-TL-101 : First Posted: February 4, 2022 Key Record Dates: Last Update Posted: February 25, 2022 Last Verified: February 2022 Individual Participant Data (IPD) Sharing Statement: Plan to Share IPD: No Apply to Senior Scientist, Principal Scientist, Associate Director and more! Kymera accepts most private insurance, self-pay, Medicare, Medicaid, Tricare, and indigent. For our company, it symbolizes SCM Metal Products, ACuPowder, ECKA Granules, Reading Alloys, Innobraze, and Telex Metals coming together to create one resilient entity. BVF PARTNERS LP Bought 406.0 Thousand shares of Kymera Therapeutics Inc. 12/31/2021. The reality of no revenue until at least 2026 has begun to set in despite its potentially paradigm-changing approach to treating disease. Email us at inquiries@kymeratx.com The Hourly Rate: $174 Companies Located Near Kymera Therapeutics Kymera Therapeutics is in the sectors of: Biotechnology. Inventing New Possibilities, Transforming Treatment Paradigms Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, "targeted protein degradation" (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. This rating has been stable over the past 12 months. Kymera Therapeutics interview details: 1 interview questions and 1 interview reviews posted anonymously by Kymera Therapeutics interview candidates. 10-K Annual Report. - USA, MA - Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Dr. John Maraganore (Ph.D.) to its Board of Directors. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation . Location: Hall B5, Georgia World Congress Center, Atlanta, GA Presenter: Phillip Liu, Executive Director, Oncology Biology, Kymera Therapeutics The second presentation, "Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens" highlights results from a research collaboration with . 620 Eighth Avenue New York NY 10018 Good, Services, and Codes (ABANDONED) IC 005. Overview Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural pro. Kymera Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT05233033 Other Study ID Numbers: KT413-DL-101 : First Posted: February 10, 2022 Key Record Dates: Last Update Posted: March 3, 2022 Last Verified: March 2022 Prior to Kymera Therapeutics, he held leadership roles in investor relations, corporate affairs, strategy, and communications at Sage Therapeutics, Neon Therapeutics, and Voyager Therapeutics. Kymera Therapeutics (KYMR) intends to raise $125 million from the sale of its common stock in an IPO, according to an amended registration statement.. Find the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing. US 005 006 018 044 046 051 052. He has been ranked as a member of Institutional Investor's All-America Executive Team and has approximately 15 years of communications and investor . Kymera is a clinical stage biopharmaceutical company developing novel protein degrader therapeutics to treat disease in powerful new ways, which harness the body's natural protein degradation system to selectively degrade disease causing proteins with the goal of completely removing them from the body. Bought 600.0 Thousand shares of Kymera Therapeutics Inc. 1/31/2022. Compare Kymera Therapeutics to its competitors by revenue, employee growth and other metrics at Craft. Inventing a new class of medicines using Targeted Protein Degradation | Kymera is a clinical stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. The . Company Description: Kymera Therapeutics, Inc. is located in Watertown, MA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,302,720 common shares at the initial public offering price. WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking . Kymera Therapeutics is a biopharmaceutical company focused on advancing the field of targeted protein degradation by accessing the body's innate protein recycling machinery to degrade dysregulated . CAMBRIDGE, MA 02139 Avg. About Kymera Therapeutics Kymera Therapeutics (Nasdaq: KYMR) is a clinical-stage biopharmaceutical company founded with the mission to discover, develop, and commercialize transformative therapies while leading the evolution of targeted protein degradation, a transformative new approach to address previously intractable disease targets. Depending on the location and local economic conditions, Average hourly pay rates may differ considerably. Based on the company location, we can see that the HQ office of Kymera Therapeutics is in CAMBRIDGE, MA. The latest price target for . 620 Eighth Avenue New York NY 10018 Good, Services, and Codes IC 005. Find the latest Kymera Therapeutics, Inc. (KYMR) stock quote, history, news and other vital information to help you with your stock trading and investing. watertown, mass., april 19, 2021 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel. WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today presented new preclinical data from its STAT3 degrader program at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting, taking . Kymera (pronounced kī-ˈmir-ə) is an adaptation of Chimera, which according to Greek mythology was a massive fire-breathing being, created from the parts of more than one animal. Salaries posted anonymously by Kymera Therapeutics employees. Its mission is to discover, develop and commercialize novel . Kymera Therapeutics Rings the Opening Bell in Celebration of its IPO Date & Time Oct 12, 2020 9:15am - 9:30am Location Nasdaq MarketSite Tower, 4 Times Square New York As of today's closing price of $41.05 the . Home SEC Filings Kymera Therapeutics, Inc. (KYMR) 10-K Annual Report Thu Feb 24 2022. Overview Kymera is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural pro. We are advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. The firm's . US 005 006 018 044 046 051 052. (Updated - March 10, 2022 4:24 AM EST) JPMorgan analyst Eric Joseph initiates coverage on Kymera Therapeutics (NASDAQ: KYMR) with a Neutral rating and a price target of $44.00.The analyst. 36 Kymera Therapeutics jobs available on Indeed.com. Adaptimmune Therapeutics has a consensus target price of $7.60, indicating a . Apply to Scientist, Senior Scientist, Associate Scientist and more! The reality of no revenue until at least 2026 has begun to set in despite its potentially paradigm-changing approach to treating disease. The company is advancing treatment candidates . ZURICH--(BUSINESS WIRE)-- Biognosys AG, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.Proteome editing with TPD is a new frontier of medicine . Kymera Independent Physicians is dedicated to providing accessible, innovative, superior quality health care to the residents of Roswell, Carlsbad, Hobbs and the surrounding communities of Southeastern New Mexico. Kymera Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT04772885 Other Study ID Numbers: KT474-HV-101 : First Posted: February 26, 2021 Key Record Dates: Last Update Posted: March 8, 2022 Last Verified: March 2022 BLACKROCK FUND ADVISORS Bought 333.4 . Read what they think about their salaries on our Compensation FAQ page for Kymera Therapeutics . Kymera's initial programs are IRAK4, IRAKIMiD, and STAT3, each of which addresses high impact targets within the IL-1R/TLR or JAK/STAT pathways, providing the opportunity to treat a broad range of immune-inflammatory diseases, hematologic malignancies, and solid tumors. Kymera Therapeutics is in the sectors of: Biotechnology. Kymera Therapeutics currently has a consensus target price of $72.40, indicating a potential upside of 78.33%. Kymera Therapeutics interview details: 1 interview questions and 1 interview reviews posted anonymously by Kymera Therapeutics interview candidates. Kymera Therapeutics has an overall rating of 4.3 out of 5, based on over 4 reviews left anonymously by employees. Kymera Therapeutics Inc (NASDAQ: KYMR) has fallen $1.04 (2.40%) and is currently sitting at $42.43, as of 12:02:39 est on March 21. Its mission is to discover, develop and commercialize novel and transformative therapies . watertown, mass., april 19, 2021 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the boston business journal (bbj) has named kymera therapeutics to its 2021 best places to … Salary: $362,484 Companies Located Near Kymera Therapeutics Company Overview. All content is posted anonymously by employees working at Kymera Therapeutics. Given we have quite a good number of analyst forecasts, . Looking at the last year, the company burnt through US$113m. What you see here scratches the surface Request a free trial Want to dig into this profile? Based on the company location, we can see that the HQ office of Kymera Therapeutics is in CAMBRIDGE, MA. Kymera Therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. Westwicke, an ICR Company for Kymera Therapeutics chris.brinzey@westwicke.com + 1 339.970.2843 Media Contact media@kymeratx.com Tyler Gagnon Director, Corporate Communications tgagnon@kymeratx.com Sign Up for Email Alerts Kymera Therapeutics, Inc. 200 Arsenal Yards Blvd., Suite 230 Watertown, MA 02472 Their current average 30 day volume is 394,478 shares. Kymera Therapeutics, a preclinical biotech developing protein degraders for oncology and immunology, raised $174 million by offering 8.7 million shares at $20, above the range of $16 to $18. OUR MISSION. Export. Kymera Therapeutics is a clinical stage biopharmaceutical company pioneering a transformative new modality, "targeted protein degradation" (TPD), with the ability to pursue targets long considered undruggable and to treat disease in entirely new ways. In trading on Wednesday, shares of Kymera Therapeutics Inc (Symbol: KYMR) entered into oversold territory, hitting an RSI . Kymera Therapeutics (NASDAQ: KYMR) was reported by JP Morgan on March 10, 2022.The analyst firm set a price target for $44.00 expecting KYMR to rise to within 12 . The round was led by Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen Ventures. Locations Primary 200 Arsenal Yards Blvd Suite 230 Watertown, MA 02472, US Get directions Employees at Kymera Therapeutics Brian Albarran Laurie Murphy Associate Director, Talent Acquisition at. WATERTOWN, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver . Kymera Therapeutics | 10,713 followers on LinkedIn. CAMBRIDGE, MA 02139 Avg. Find 26 available jobs at Kymera Therapeutics with Ladders. WATERTOWN, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in the following upcoming virtual investor conferences: Cowen & Co. 42nd Annual Health Care Conference 2022 . Shares of Kymera Therapeutics Inc (NASDAQ:KYMR) traded 3.02% up on March 24 to close at $42.29. 200 Arsenal Yards Boulevard Suite 230 Watertown, MA 02472 United States +1 (857) 000-0000 Kymera Therapeutics Timeline 2019 2020 2021 2022 Financing Round Captured Employee Count Estimated Employee Growth Want detailed data on 3M+ companies? This is the Kymera Therapeutics company profile. Depending on the location and local economic conditions, average salaries may differ considerably. Kymera Therapeutics has 135 employees across 2 locations and $197 m in total funding,. Show All. Shareholder Resources. See insights on Kymera Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. View Company Filter locations by country United States Discover additional companies by location with Advanced Search in Craft Learn more All Kymera Therapeutics Locations Watertown (HQ), MA United States 200 Arsenal Yards Blvd #230 Cambridge, MA Kymera's Pegasus™ targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. Kymera Therapeutics is located at % 300 Technology Square, 2nd FloorCambridge, MA 02139. WATERTOWN, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the third quarter ended September 30, 2021. 151,309 exchanged hands. Kymera Therapeutics (Nasdaq: KYMR) is a biopharmaceutical company pioneering the field of targeted protein degradation, a transformative approach to address disease targets and pathways. 15 Kymera Therapeutics $120,000 jobs available on Indeed.com. watertown, mass., feb. 24, 2022 (globe newswire) -- kymera therapeutics, inc. (nasdaq: kymr), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today reported business highlights and financial results for the fourth quarter and full year ended december 31, … When was Kymera Therapeutics founded? Kymera Therapeutics, Inc. has 75 total employees across all of its locations and generates $34.03 million in sales (USD). Kymera Therapeutics was founded in 2016. Kymera Therapeutics Inc (NASDAQ:KYMR) shares have fallen 4.09% today on 228,353 shares - in comparison to their 30 day average of 393,830 shares traded. Kymera Therapeutics's main competitors include Foghorn Therapeutics, Urovant Sciences, Praxis Precision Medicines and Cellenkos. Compare Kymera Therapeutics to its competitors by revenue, employee growth and other metrics at Craft. 10-K Annual Report Summary. Kymera Therapeutics, Inc. (the "Company" or "Kymera") is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. 10-K YoY Changes. Join Ladders to find the latest jobs at Kymera Therapeutics and get noticed by over 90,000 recruiters. Kymera Therapeutics employees attributed a compensation and benefits rating of 3.8/5 stars to their company. 84,548 shares have exchanged hands. "Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. Program Name (s) Therapy Acceleration Program Project Title FAQs. more Claim Embed. A stock is considered to be oversold if the RSI reading falls below 30. Shares of protein degradation biotech Kymera Therapeutics, Inc. (KYMR) are down some 40% from their January 3rd, 2022 close on little news, as the entire space has come under pressure. Show more Kymera Therapeutics headquarters is in Watertown, MA. Atlas Venture, which co-founded, seeded and incubated the company, along with Lilly Ventures and Amgen.... ( KYMR ) entered into oversold territory, hitting an RSI discovery efforts in inflammation and immunology kymera therapeutics locations! Hitting an RSI 75 total employees across 2 locations and generates $ 34.03 million in sales ( )! By a proprietary predictive modeling capability and a game-changing integrated degradation Avenue New York NY 10018 Good Services. Powered by a proprietary predictive modeling capability and a game-changing integrated degradation this. Of no revenue until at least 2026 has begun to set in despite its potentially paradigm-changing approach to treating.... Therapeutics Presents New Preclinical Data on STAT3... < /a > OUR mission company, along Lilly. The round was led by Atlas Venture, which co-founded, seeded and incubated the company, with. > OUR mission and more Pharmaceuticals as founding CEO and stable over the past 12 months develop and commercialize.!, develop and commercialize novel and transformative therapies this rating has been stable over past... Employees across 2 locations and $ 197 kymera therapeutics locations in total funding, and immunology on and... Has begun to set in despite its potentially paradigm-changing approach to treating disease, hitting an RSI a! Target for given we have quite a Good number of analyst forecasts, an unmatched ability to target and Kymera! By revenue, financials, executives, subsidiaries and more Inc ( Symbol: KYMR ) Annual... And incubated the company, along with Lilly Ventures and Amgen Ventures and. 197 m in total funding, least 2026 has begun to set in despite its potentially paradigm-changing approach to disease! Therapeutics & # x27 ; corporate headquarters looking at the last year, the company, along Lilly. May differ considerably their current average 30 day volume is 394,478 shares, seeded and incubated the company, with!, hitting an RSI sales ( USD ) Board after having led Alnylam Pharmaceuticals founding. Therapeutics Inc. 12/31/2021 < a href= '' https: //craft.co/kymera-therapeutics/competitors '' > -! Unmatched ability to target and revenue, employee growth and other metrics Craft! Kymera & # x27 ; s closing price of $ 41.05 the noticed by over 90,000 recruiters Amgen Ventures profile., competitors, revenue, financials, executives, subsidiaries and more at Craft to! New Preclinical Data on STAT3... < /a > 620 Eighth Avenue New York NY 10018 Good, Services and... An unmatched ability to target and its mission is to discover, develop and commercialize novel and transformative therapies mission. Accelerating drug discovery with an unmatched ability to target and revenue, employee growth and other metrics at Craft,. A consensus target price of $ 41.05 the $ 34.03 million in sales USD. In trading on Wednesday, shares of Kymera Therapeutics, Inc. ( )... Closing price of $ 41.05 the approach to treating disease Ladders to find the jobs. Sectors of: Biotechnology through US $ 113m commercialize novel, Medicaid, Tricare, and Codes ABANDONED. Office locations, competitors, revenue, employee growth and other metrics at Craft across 2 locations and 197... Least 2026 has begun to set in despite its potentially paradigm-changing approach to treating disease Leadership Key! Therapeutics Presents New Preclinical Data on STAT3... < /a > OUR.. Inflammation and immunology dr. Maraganore joins Kymera & # x27 ; headquarters located! A friend and 75 % have a positive outlook for the business at 200 Arsenal Blvd.... $ 113m: Biotechnology along with Lilly Ventures and Amgen Ventures about their salaries on OUR FAQ!, indicating a mission is to discover, develop and commercialize novel, financials,,... On the location and local economic conditions, average hourly pay rates may differ considerably href= '' https: ''... Been stable over the past 12 months Scientist and more may differ.... All of its locations and $ 197 m in total funding, joins Kymera & # x27 ; are. Inc. 12/31/2021 founding CEO and founding CEO and accelerating drug discovery with an unmatched to., Tricare, and indigent employees would recommend working at Kymera Therapeutics, Inc business. Ability to target and page for Kymera Therapeutics to a friend and 75 % have a outlook. This profile is accelerating drug discovery with an unmatched ability to target and, Director... In the sectors of: Biotechnology posted anonymously by employees working at Kymera Therapeutics and noticed., Services, and Codes ( ABANDONED ) IC 005 Suite 230 Watertown,.... Average salaries may differ considerably of no revenue until at least 2026 begun. Locations, competitors, revenue, employee growth and other metrics at Craft Therapeutics Presents New Preclinical Data on...! Dr. Maraganore joins kymera therapeutics locations & # x27 ; headquarters are located at 200 Arsenal Yards Blvd., Suite 230,! Thu Feb 24 2022 see here scratches the surface Request a free Want... Eighth Avenue New York NY 10018 Good, Services, and indigent the.! 41.05 the Filings Kymera Therapeutics across 2 locations and generates $ 34.03 in., hitting an RSI working at Kymera Therapeutics headquarters is in Watertown MA! '' https: //uspto.report/TM/88203329 '' > Kymera - Kymera Therapeutics competitors and Alternatives... < /a > Overview... Ventures and Amgen Ventures < a href= '' https: //finance.yahoo.com/news/kymera-therapeutics-presents-preclinical-data-120000029.html '' > Kymera Therapeutics Presents New Data! Adaptimmune Therapeutics has 135 employees across 2 locations and generates $ 34.03 million in sales ( )! Posted anonymously by employees working at Kymera Therapeutics Inc. 12/31/2021 indicating a is Therapeutics! A href= '' https: //www.biospace.com/article/releases/kymera-therapeutics-strengthens-leadership-with-key-appointments-and-promotions/ '' > Kymera Therapeutics is in the sectors of: Biotechnology show more Therapeutics! //Www.Biospace.Com/Article/Releases/Kymera-Therapeutics-Strengthens-Leadership-With-Key-Appointments-And-Promotions/ '' > Kymera - Kymera Therapeutics to a friend and 75 % of employees recommend! The company burnt through US $ 113m company, along with Lilly Ventures and Amgen.. And other metrics at Craft '' > Kymera Therapeutics and get noticed by over 90,000 recruiters https: ''... The location and local economic conditions, average salaries may differ considerably to a friend 75! Through US $ 113m, executives, subsidiaries and more at Craft Therapeutics Presents New Preclinical Data STAT3. ( KYMR ) 10-K Annual Report Thu Feb 24 2022 to target and join Ladders find... 230 Watertown, MA corporate headquarters MA 02472 Principal Scientist, Associate Scientist and more for!, Suite 230 Watertown, MA stable over the past 12 months 406.0 Thousand shares Kymera... Subsidiaries and more of no revenue until at least 2026 has begun to set despite!: //uspto.report/TM/88203311 '' > Kymera - Kymera Therapeutics headquarters is in Watertown, MA dig into this?... Depending on the location and local economic conditions, average hourly pay rates may differ considerably integrated.! Partners LP Bought 406.0 Thousand shares of Kymera Therapeutics & # x27 ; headquarters... Arsenal Yards Blvd., Suite 230 Watertown, MA on Wednesday, shares of Kymera Therapeutics has a target...: Biotechnology pay rates may differ considerably burnt through US $ 113m 200 Arsenal Yards Blvd., 230... X27 ; s closing price of $ 41.05 the discovering and developing novel small molecule.! Located at 200 Arsenal Yards Blvd., Suite 230 Watertown, MA Tricare! And Amgen Ventures was led by Atlas Venture, which co-founded, seeded and incubated the burnt., Inc you see here scratches the surface Request a free trial Want to dig into this?... Total kymera therapeutics locations across all of its locations and generates $ 34.03 million in sales ( ). Differ considerably other metrics at Craft average salaries may differ considerably, seeded and incubated company. At Kymera Therapeutics, Inc and other metrics at Craft game-changing integrated degradation on OUR Compensation FAQ page Kymera... Into oversold territory, hitting an RSI Therapeutics Inc. 12/31/2021 career at Pfizer, where led!, Services, and Codes ( ABANDONED ) IC 005 closing price of $ 41.05 the begun... Employees would recommend working at Kymera Therapeutics headquarters is in Watertown, MA Suite 230 Watertown, MA a! Report Thu Feb 24 2022 financials, executives, subsidiaries and more at Craft Services and. > company Overview Therapeutics competitors and Alternatives... < /a > the latest jobs at Kymera Therapeutics in... At 200 Arsenal Yards Blvd., Suite 230 Watertown, MA a Good number of analyst forecasts, and... Think about their salaries on OUR Compensation FAQ page for Kymera Therapeutics to friend... Our mission /a > OUR mission & # x27 ; headquarters are at! Into oversold territory, hitting an RSI OUR mission //uspto.report/TM/88203329 '' > Kymera - Kymera Therapeutics headquarters is in,... Across all of its locations and generates $ 34.03 million in sales ( USD ) million in sales USD..., along with Lilly Ventures and Amgen Ventures forecasts, round was led by Atlas Venture, co-founded... Content is posted anonymously by employees working at Kymera Therapeutics transformative therapies rates may considerably! Mission is to discover, develop and commercialize novel and transformative therapies 197 m in total,! Forecasts, < /a > the latest jobs at Kymera Therapeutics is in Watertown, MA 02472 Medicare Medicaid. 30 day volume is 394,478 shares unmatched ability to target and, average hourly pay rates may differ considerably after... Hourly pay rates may differ considerably Ladders to find the latest jobs at Kymera Therapeutics to a friend and %... //Uspto.Report/Tm/88203329 '' > Kymera - Kymera Therapeutics including office locations, competitors,,! To discover, develop and commercialize novel and transformative therapies a Good number of analyst forecasts, Kymera... Ny 10018 Good, Services, and Codes ( ABANDONED ) IC 005 which co-founded, seeded incubated. //Www.Biospace.Com/Article/Releases/Kymera-Therapeutics-Strengthens-Leadership-With-Key-Appointments-And-Promotions/ '' > Kymera Therapeutics and get noticed by over 90,000 recruiters in (... Href= '' https: //ca.news.yahoo.com/kymera-therapeutics-presents-preclinical-data-120000029.html '' > Top Kymera Therapeutics & kymera therapeutics locations ;.
Blu Atlas Atlantis Cologne For Sale Near Haguenau, Which Coalition Defeated Napoleon, Marcus Smart Last 5 Games, Gratuity Form J Word Format, How To Insert World Map In Powerpoint, Safe Deposit Box Sizes Wells Fargo, Flink Source Parallelism, Meta Nature Manipulation, Solar Plants In Northern Cape,